Sign In
Buy FENC
$9.14
-0.84 (-8.42%)
At Close: Jun 03, 2026
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) Price Target at $13.33
02:10am, Sunday, 30'th Nov 2025
Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five brokerages that are covering the firm, Marketbeat reports. Tw
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
05:59am, Wednesday, 26'th Nov 2025
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
07:03am, Wednesday, 19'th Nov 2025
RESEARCH TRIANGLE PARK, N. C. , Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC) (TSX: FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
04:15pm, Monday, 17'th Nov 2025
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today annou
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
11:11pm, Thursday, 13'th Nov 2025
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today annou
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
11:07pm, Thursday, 13'th Nov 2025
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today annou
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates
06:11pm, Thursday, 13'th Nov 2025
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.21 per share a year ago.
Fennec Pharmaceuticals Announces Proposed Offering of Common Shares
04:08pm, Thursday, 13'th Nov 2025
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today annou
Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
11:07am, Thursday, 30'th Oct 2025
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for Oct. 15th
05:20am, Wednesday, 15'th Oct 2025
FENC, BABA and ALCO have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2025.
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
10:46am, Friday, 19'th Sep 2025
Investors need to pay close attention to Adherex Technologies stock based on the movements in the options market lately.
Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
03:34pm, Tuesday, 19'th Aug 2025
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Jeffrey S. Hackman - CEO & Director Robert C.
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates
08:21am, Thursday, 14'th Aug 2025
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
06:08am, Thursday, 14'th Aug 2025
~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Pr
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
07:12am, Monday, 11'th Aug 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp
